Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Novo Nordisk, the manufacturer behind Ozempic and Wegovy, has another weight loss medication in the works with some ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

丹麦制药公司诺和诺德（Novo Nordisk A/S）周五报告称，该公司下一代减肥药之一monlunabant在较高剂量时减重效果有限，而且有一定副作用，导致该公司股价周五下跌。

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

European shares slipped on Friday (Sep 20) after a rally in the previous session spurred by the US Federal Reserve’s outsized ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

“特别声明：以上作品内容(包括在内的视频、图片或音频)为凤凰网旗下自媒体平台“大风号”用户上传并发布，本平台仅提供信息存储空间服务。 Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which ...

Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

EU officials are preparing charges against Google for antitrust violations in how it displays rival product results.